Home/Filings/4/0001123292-13-001613
4//SEC Filing

K-V Pharmaceutical Co 4

Accession 0001123292-13-001613

CIK 0000057055operating

Filed

Nov 19, 7:00 PM ET

Accepted

Nov 20, 5:49 PM ET

Size

8.1 KB

Accession

0001123292-13-001613

Insider Transaction Report

Form 4
Period: 2013-11-18
Transactions
  • Purchase

    Common Stock

    2013-11-18$46.50/sh+25,000$1,162,5002,023,883 total
Transactions
  • Purchase

    Common Stock

    2013-11-18$46.50/sh+25,000$1,162,5002,023,883 total
MULE EDWARD A
10% Owner
Transactions
  • Purchase

    Common Stock

    2013-11-18$46.50/sh+25,000$1,162,5002,023,883 total
Footnotes (1)
  • [F1]Silver Point Capital, L.P. ("Silver Point") is the investment manager of Silver Point Capital Fund, L.P. and Silver Point Capital Offshore Fund, Ltd. (the "Funds") and, by reason of such status, may be deemed to be the beneficial owner of all of the reported securities held by the Funds. Silver Point Capital Management, LLC ("Management") is the general partner of Silver Point and as a result may be deemed to be the beneficial owner of all securities held by the Funds. Messrs. Edward A. Mule and Robert J. O'Shea are each members of Management and as a result may be deemed to be the beneficial owner of all of the securities held by the Funds. Silver Point, Management and Messrs. Mule and O'Shea disclaim beneficial ownership of the reported securities held by the Funds except to the extent of their pecuniary interests.

Issuer

K-V Pharmaceutical Co

CIK 0000057055

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000057055

Filing Metadata

Form type
4
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 5:49 PM ET
Size
8.1 KB